Partners
Cellzome has entered into five partnerships with leading health care companies to date:
- GSK has entered two worldwide strategic alliances with Cellzome to discover, develop and market novel therapeutics to treat inflammatory diseases. The first collaboration focuses on kinases using Cellzome's Kinobeads™ technology, while the second one uses Cellzome's Episphere™ technology to address epigenetic targets.
- Novartis and Cellzome collaborated over four years to identify new drug targets and leads in a variety of disease areas by applying the Cellzome pathway mapping and chemical proteomics technologies. The alliance was successfully completed in June 2008.
- Johnson & Johnson PRD: Collaboration in Alzheimers's Disease was successfully completed in
March 2010. - Bayer HealthCare: Collaboration successfully completed.
We also have links with several internationally recognized academic institutions, such as the European Molecular Biology Laboratory, Medical Research Council (Dundee), Harvard Medical School, MIT/Withehead Institute for Biomedical Research, Howard Hughes Medical Institute, the Universities of Birmingham, Cologne, Munich, San Francisco, Torino, Imperial College, and the Center for Molecular Medicine in Vienna.
Cellzome is interested in exploring strategic drug discovery collaborations based on its Kinobeads™ and Episphere™ technologies. For additional information and opportunities please contact business@cellzome.com